Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/14/2025

Hypertension Management after Coronary Artery Bypass Grafting (CABG)

Introduction to Hypertension Management

  • The American College of Cardiology and American Heart Association recommend that ACE inhibitors/ARBs should be reinstituted postoperatively once the patient is stable after CABG, especially in patients with low ejection fraction, hypertension, diabetes mellitus, or chronic kidney disease 2
  • The American College of Cardiology and American Heart Association suggest that beta-blockers should be reinstituted as soon as possible after CABG in patients without contraindications 2

Medication Management

  • For patients with persistent uncontrolled hypertension after CABG on ACE inhibitors, the American College of Cardiology recommends adding dihydropyridine CCBs (if angina is present) and thiazide diuretics 5
  • The American College of Cardiology recommends a target blood pressure of <130/80 mmHg in patients with coronary artery disease 5
  • Current guidelines for post-CABG hypertension management recommend beta-blockers, ACE inhibitors/ARBs, dihydropyridine CCBs, and thiazide diuretics as the preferred agents for hypertension management in CAD patients 1, 5

Optimizing Therapy

  • The American Heart Association suggests optimizing current therapy first by increasing ACE inhibitor dose if not at maximum and ensuring adequate dosing of current CCB 1, 2, 5
  • The American College of Cardiology recommends adding a thiazide-like diuretic, such as chlorthalidone 12.5-25mg daily, which has the strongest evidence base for reducing cardiovascular outcomes 6
  • Consider adding a beta-blocker, particularly if the patient has a history of prior MI or stable angina, with cardioselective beta-blockers (metoprolol succinate) being preferred 1, 5

Resistant Hypertension

  • For resistant hypertension, consider adding spironolactone 25mg daily if kidney function is adequate (eGFR >45 mL/min) 6

Monitoring and Follow-up

  • Check blood pressure within 2-4 weeks after medication changes and monitor for potential adverse effects, such as hypotension, electrolyte abnormalities, and bradycardia 6